Vials maker Schott Pharma slides on 2025 profit warning

Stevanato SpA

15/05/2024 08:52

** Shares in Schott Pharma  1SXP.DE  fall 15%, on track for
their worst day since their listing in September if losses hold,
after the German medical vials maker cut 2025 target on Tuesday
    ** Schott Pharma posts H1 revenue of 489 million euros ($529
million), up 9% year-on-year, and reiterates its FY24 guidance 
    ** It now expects a high single-digit to low double-digit
percent revenue growth for 2025, impacted by slower growth from
in its syringes business
    ** That is below consensus expectations for "high teens"
percentage, which is around 17%, Jefferies writes
    ** Vials manufacturers have come under pressure recently,
with Italian group Stevanato  STVN.N  also issuing a profit
warning, Jefferies adds
    ** "Very low visibility mid-term weighs on shares heftily,"
a local trader says, after shares fell 11% in extended trading
on Tuesday
    
($1 = 0.9236 euros)

 (Reporting by Eva Orsolya Papp)
 ((evaorsolya.papp@thomsonreuters.com))